Compare · RGNX vs SLDB
RGNX vs SLDB
Side-by-side comparison of REGENXBIO Inc. (RGNX) and Solid Biosciences Inc. (SLDB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RGNX and SLDB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SLDB is the larger of the two at $695.3M, about 1.5x RGNX ($478.7M).
- RGNX has been more active in the news (10 items in the past 4 weeks vs 9 for SLDB).
- RGNX has more recent analyst coverage (24 ratings vs 19 for SLDB).
- Company
- REGENXBIO Inc.
- Solid Biosciences Inc.
- Price
- -
- -
- Market cap
- $478.7M
- $695.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2018
- News (4w)
- 10
- 9
- Recent ratings
- 24
- 19
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Solid Biosciences Inc.
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Latest RGNX
- SEC Form SCHEDULE 13G filed by REGENXBIO Inc.
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
- Chief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)
- Chief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)
- Chief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)
- REGENXBIO to Participate in Stifel 2026 Healthcare Conference
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
Latest SLDB
- SEC Form SCHEDULE 13G filed by Solid Biosciences Inc.
- Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
- William Blair resumed coverage on Solid Biosciences
- Amendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.
- Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Solid Biosciences Inc.
- SEC Form 4 filed by Solid Biosciences Inc.
- Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
- Chief Medical Officer Brooks Gabriel sold $24,582 worth of shares (4,374 units at $5.62) as part of a pre-agreed trading plan (SEC Form 4)